Omada Health, Inc. (NASDAQ:OMDA – Get Free Report) CFO Steven Cook sold 12,337 shares of the business’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $23.09, for a total value of $284,861.33. Following the completion of the sale, the chief financial officer owned 187,209 shares in the company, valued at approximately $4,322,655.81. The trade was a 6.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Omada Health Stock Performance
OMDA stock opened at $22.98 on Thursday. The company has a market capitalization of $1.37 billion and a price-to-earnings ratio of -85.11. Omada Health, Inc. has a fifty-two week low of $10.28 and a fifty-two week high of $26.92. The stock has a fifty day moving average of $17.83 and a 200-day moving average of $15.27.
Omada Health (NASDAQ:OMDA – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.03. The business had revenue of $78.05 million for the quarter. Omada Health had a negative return on equity of 1.82% and a negative net margin of 2.22%. Equities analysts predict that Omada Health, Inc. will post -0.01 EPS for the current year.
Institutional Investors Weigh In On Omada Health
Wall Street Analyst Weigh In
A number of brokerages recently commented on OMDA. Evercore restated an “outperform” rating and set a $20.00 price target on shares of Omada Health in a research note on Friday, May 8th. Canaccord Genuity Group set a $24.00 target price on Omada Health in a research note on Friday, May 8th. Wells Fargo & Company lifted their target price on Omada Health from $17.00 to $18.00 and gave the company an “equal weight” rating in a report on Friday, May 8th. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price target on shares of Omada Health in a research report on Friday, May 8th. Finally, The Goldman Sachs Group reissued a “buy” rating on shares of Omada Health in a report on Friday, May 8th. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.91.
Get Our Latest Stock Report on OMDA
Omada Health Company Profile
Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.
In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.
Read More
- Five stocks we like better than Omada Health
- A Market Panic Just Discounted the AI Highway’s Tollbooth
- Why Exxon Could Be the Market’s Next Big Comeback Stock
- The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
- Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns
Receive News & Ratings for Omada Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omada Health and related companies with MarketBeat.com's FREE daily email newsletter.
